Review article<br>Place of exenatide in the treatment of type 2 diabetic patients

Marta Wróbel; Aleksandra Szymborska-Kajanek; Władysław Grzeszczak; Krzysztof Strojek

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Abstracting and indexing Contact Instructions for authors

4/2007
vol. 2

Send email

Copy url:

abstract:

Review article
Place of exenatide in the treatment of type 2 diabetic patients

Marta Wróbel

,

Aleksandra Szymborska-Kajanek

,

Władysław Grzeszczak

,

Krzysztof Strojek

Przegląd Kardiodiabetologiczny 2007; 2, 4: 234–240

Online publish date: 2007/12/21

View full text Get citation

Type 2 diabetes is a serious medical problem nowadays, particularly when considering increasing number of diabetic patients in the world. Previous therapy of this disease, beside behavioral treatment, was based on oral antidiabetic agents and insulin as monotherapy or combination. Currently incretin hormons are of significant interest. These are gut hormones which stimulate β cells to insulin secretion in a glucose-dependent manner. Exenatid – GLP-1 receptor agonist – is a representative of new group of agents which improve incretin effect. The aim of the article was to define role of this drug in the treatment of type 2 diabetic patients

keywords:

Review articlePlace of exenatide in the treatment of type 2 diabetic patients

Marta Wróbel , Aleksandra Szymborska-Kajanek , Władysław Grzeszczak , Krzysztof Strojek

type 2 diabetes, GLP-1 receptor agonist, incretin hormones

Review article
Place of exenatide in the treatment of type 2 diabetic patients

Marta Wróbel

,

Aleksandra Szymborska-Kajanek

,

Władysław Grzeszczak

,

Krzysztof Strojek